Corbus Pharmaceuticals Holdings, Inc.
NASDAQ:CRBPBiotechnology
Healthcare
$2.44 +1.73%
+$0.14 today
- Market cap
- $50.18M
- Beta
- 2.59
- P/E (TTM)
- -1.3
- EPS (TTM)
- -$6.35
52W Low $6.72High $20.56
Volume 0.66M
Average 0.42M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$64.49M
FY 2025 · Annual
Investing Cash Flow
-$1.64M
FY 2025 · Annual
Financing Cash Flow
$77.43M
FY 2025 · Annual
-53.5% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (45.64M) | (42.35M) | (44.6M) | (40.21M) | (78.54M) |
| Depreciation & Amortization | 1.64M | 1.49M | 641K | (2.74M) | (1.13M) |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 9.48M | 5.72M | 3.47M | 6.15M | 6.29M |
| Change in Working Capital | (15.7M) | (4.02M) | 4.09M | (5.58M) | 9.12M |
| Accounts Receivables | 1.62M | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | (5.96M) | (256.84K) | 1.03M | 1.6M | (2.35M) |
| Other Working Capital | (11.36M) | (3.77M) | 3.07M | (7.18M) | 11.47M |
| Other Non-Cash Items | 2.03M | 1.62M | 3.77M | 585K | (229K) |
| Operating Cash Flow | (48.18M) | (37.54M) | (36.1M) | (41.79M) | (64.49M) |
| Capital Expenditures | (54.17K) | (13.45K) | 3 | 0 | (7K) |
| Acquisitions (Net) | 0 | 8.1K | 0 | 0 | 0 |
| Purchases of Investments | (87.27M) | (86.34M) | (33.88M) | (180.8M) | (163.09M) |
| Sales of Investments | 13.88M | 116.42M | 69.53M | 59.49M | 161.46M |
| Other Investing Activities | 23.9K | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (73.42M) | 30.07M | 35.64M | (121.31M) | (1.64M) |
| Debt Repayment | 57.78K | (533.62K) | (2.87M) | (15.48M) | 0 |
| Common Stock Issued | 62.59M | 0 | 53.4K | 182.06M | 77.43M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.82M) | 0 | 0 | 0 | 0 |
| Financing Cash Flow | 60.82M | (533.62K) | (2.82M) | 166.58M | 77.43M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (60.78M) | (8M) | (3.28M) | 3.47M | 11.29M |
| Free Cash Flow | (48.24M) | (37.56M) | (36.1M) | (41.79M) | (64.5M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$78.5M
+ D&A-$1.1M
+ Stock-Based Comp$6.3M
+ Deferred Tax$0
+ Working Capital$9.1M
- Other Non-Cash-$229.0K
= Operating Cash Flow-$64.5M
- Capex-$7.0K
= Free Cash Flow-$64.5M
Analysis
FY2025 free cash flow is -$64.5M. FCF conversion is 82.1% of net income. Operating cash flow was -$64.5M, with capex of -$7.0K. The largest bridge item is Working Capital at $9.1M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| SC 13G | SC 13G filing | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 10, 2026 | |
| 8-K | Current report | Nov 10, 2026 | |
| 4 | Statement of changes in beneficial ownership | Nov 2, 2026 | |
| SC 13G/A | SC 13G/A filing | Nov 2, 2026 |
Does CRBP generate free cash flow?
Corbus Pharmaceuticals Holdings, Inc. (CRBP) generated -$64.50M of free cash flow in fiscal 2025.
How much operating cash flow does CRBP produce?
Operating cash flow was -$64.49M, before capital expenditures of $7,000.00.
Continue the stock analysis
Jump to another research area for this company.